Potential Biomarkers to Distinguish Type 1 Myocardial Infarction in Troponin-Elevated Diseases

Int J Mol Sci. 2023 Apr 30;24(9):8097. doi: 10.3390/ijms24098097.

Abstract

Classifying myocardial infarction by subtype is crucial for appropriate patient management. Although troponin is currently the most commonly used biomarker, it is not a specific marker for myocardial infarction and cannot distinguish subtypes. Furthermore, previous studies have confirmed that proteins known as myocardial infarction markers could function to distinguish the type of myocardial infarction. Therefore, we identify a marker that can distinguish type 1 myocardial infarction from other diseases with elevated troponin. We used mass spectrometry to compare type 1 myocardial infarction with other conditions characterized by troponin elevation and identified new candidate markers for disease classification. We then verified these markers, along with those already known to be associated with cardiovascular disease and plaque rupture. We identified α-1 acid glycoprotein 2, corticosteroid-binding globulin, and serotransferrin as potential distinguishing markers. The presence of these markers and other parameters, such as chest pain, electrocardiogram, and troponin levels from the complementary diagnostic processes, could provide valuable information to specifically diagnose type 1 myocardial infarction.

Keywords: elevated cardiac troponin; mass spectrometry; proteomics; type 1 myocardial infarction.

MeSH terms

  • Biomarkers
  • Chest Pain / diagnosis
  • Electrocardiography
  • Humans
  • Myocardial Infarction* / diagnosis
  • Troponin*

Substances

  • Troponin
  • Biomarkers

Grants and funding

The APC was funded by the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT) (No. 2020R1C1C1009196).